Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Reckitt Benckiser should enjoy 'more normalised base,' says broker

Reckitt Benckiser should enjoy a more normalised base as it comes out of three years of reinvestment, according to JP Morgan.

The US banking giant has an overweight rating on the stock with a target price set at 7,500p.

As a result, the broker increased the total shareholder returns for Reckitt by 12% to 15% per year through a combination of “leveraging its volumes-driven medium-single-digit top line and increasing cash returns” via buybacks and dividends.

The cornerstone to JP Morgan’s equity story includes evidence of improved execution and share gains as well as cash generation with increasing returns.

The flesh-out of the business has bolstered its market share gains and increased penetration, which should drive positive momentum as the consumer goods giant delivers on its innovation pipeline and benefits from improved pricing position, said the broker.

The stock trades at near three-year lows and at a 20% to 30% discount to peers, noted the broker.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK